Physician profile
Corrie L Stapleton
NPI 1225796451
$901.04
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.16 · 2022: $270 · 2023: $340 · 2024: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.13 | 2022-2023 | |
| Boston Scientific Corporation | $219.69 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $89.17 | 2022-2024 | Taltz, Mounjaro, Trulicity |
| Novo Nordisk INC | $78.43 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $35.58 | 2022-2023 | Quviviq |
| Organon LLC | $29.67 | 2022 | |
| Dexcom, INC. | $25.18 | 2024 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $21.77 | 2022 | |
| Lucid Diagnostics INC. | $18.45 | 2022 | |
| Merck Sharp & Dohme LLC | $16.81 | 2023 | Steglatro, Belsomra |
| Antares Pharma, INC. | $14.31 | 2022 | |
| Sobi, INC | $13.16 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrie Stapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.